Dr. Salman Otoukesh
Hematology (Hematology (Internal Medicine) Physician)
1500 E. Duarte Road
Duarte, CA 91010
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 169
Licensed in California since 2015, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
CA license A139997 (first issued 2015; current) -
Internal Medicine Physician
TX license BP10047617
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- City of Hope Medical Foundation (982 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 169
- Services billed
- 1,553
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 379 | 69 |
| Established patient office or other outpatient visit, 40-54 minutes | 330 | 64 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 132 | 34 |
| Established patient office or other outpatient visit, 30-39 minutes | 50 | 31 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 16 | 14 |
| Hospital discharge day management, more than 30 minutes | 15 | 15 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 38 |
| Ondansetron Hcl Other prescribers in Duarte, CA | 18 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Duarte, CA | 17 |
| Hydroxyurea Other prescribers in Duarte, CA | 17 |
| Pantoprazole Sodium Other prescribers in Duarte, CA | 16 |
| Acyclovir Other prescribers in Duarte, CA | 14 |
| Imatinib Mesylate | 14 |
| Posaconazole | 14 |
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in Duarte, CA | 11 |
| Idhifa (enasidenib mesylate) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $688 in total to this clinician.
| Daiichi Sankyo Inc. | $650 |
|---|---|
| AbbVie Inc. | $21.74 |
| Azurity Pharmaceuticals, Inc. | $16.42 |
| Consulting Fee | $650 |
|---|---|
| Food and Beverage | $38.16 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Sep 22, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $671,313 in research payments for these studies, mostly to the institutions running them.
- A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC - An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis
Geron Corporation - A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Janssen Research & Development, LLC - Study name not reported
Pharmaessentia USA Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.